Non-viral nanocarriers for siRNA delivery in breast cancer

Zhang, Jing; Li, Xiang; Huang, Leaf

doi:10.1016/j.jconrel.2014.05.037

Cited by 81 publications

(47 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[17] PEGylation of liposomes leads to greater stability of the carrier. [18] Refer to Figure 1C for the general structure of SNALPs.…”

Section: Snalpsmentioning

confidence: 99%

See 1 more Smart Citation

An Overview of Various Carriers for siRNA Delivery

Marquez¹,

Madu²,

Lü³

2018

Oncomedicine

View full text Add to dashboard Cite

RNA interference through the use of short interfering molecules known as short interfering RNA (siRNA) has the potential to greatly advance research in treatments for many diseases because it has the ability to silence the expression of specific genes by helping degrade target mRNA. However, challenges to siRNA delivery have made the development of safe and effective delivery systems paramount in siRNA research. Various types of delivery systems have been proposed and investigated for siRNA delivery and therapy. Although viral vectors have been established to be the most effective in delivering siRNA molecules, they also raise many concerns over biosafety, especially concerning immunogenicity. Therefore, many researchers have begun to investigate and study non-viral vectors. Non-viral vectors are studied because they are typically considered to be safer than viral vectors albeit less efficient as well. The three general non-viral vectors that have been studied for siRNA delivery are lipid-based, non-lipid organic-based, and non-lipid inorganic-based carriers. Within those general parameters of non-viral vector classification are subtypes that are each unique with their own characteristic benefits and downsides. Many of these carriers, as well as even naked siRNA, do have the potential to be modified so that siRNA delivery could be further enhanced with benefits such as greater stability and duration. Researchers still must be wary with alterations as to not interfere with siRNA function. Currently, widespread siRNA therapeutics are still out of reach, but as more advancements in siRNA research including research on their delivery mechanisms are established, the goal of integrating siRNA therapy into the treatment of a multitude of diseases becomes increasingly more of a possibility. Researchers are currently investigating how siRNA can be used to not just treat cancer but ocular and neurodegenerative diseases as well as many others. There are still many obstacles to face and overcome before siRNA therapy can be implemented into the treatment of many diseases, and more research must still be conducted concerning siRNA delivery systems. Many advancements pertaining to siRNA carriers have been made, and many more are likely on their way.

show abstract

“…[17] PEGylation of liposomes leads to greater stability of the carrier. [18] Refer to Figure 1C for the general structure of SNALPs.…”

Section: Snalpsmentioning

confidence: 99%

“…Afterwards, the core is then surrounded by liposomes. [18,21] Refer to Figure 1D for the general structure of an MCNP.…”

Section: Mcnpsmentioning

confidence: 99%

An Overview of Various Carriers for siRNA Delivery

Marquez¹,

Madu²,

Lü³

2018

Oncomedicine

View full text Add to dashboard Cite

show abstract

“…Breast cancer is the most frequently diagnosed type of cancer and the leading cause of cancer related death in women [118]. Breast cancer can be divided into distinct subtypes by using either immunohistochemical (IHC) staining patterns for key receptors or, more recently, molecular profiling.…”

Section: Current Targets For Sirna In Cancermentioning

confidence: 99%

Delivery strategies and potential targets for siRNA in major cancer types

Lee

Kim

Kwon

et al. 2016

Advanced Drug Delivery Reviews

119

View full text Add to dashboard Cite

Small interfering RNA (siRNA) has gained attention as a potential therapeutic reagent due to its ability to inhibit specific genes in many genetic diseases. For many years, studies of siRNA have progressively advanced toward novel treatment strategies against cancer. Cancer is caused by various mutations in hundreds of genes including both proto-oncogenes and tumor suppressor genes. In order to develop siRNAs as therapeutic agents for cancer treatment, delivery strategies for siRNA must be carefully designed and potential gene targets carefully selected for optimal anti-cancer effects. In this review, various modifications and delivery strategies for siRNA delivery are discussed. In addition, we present current thinking on target gene selection in major tumor types.

show abstract

“…1–3 The use of naked unformulated siRNA, however, is associated with several inherent problems due to the poor cellular permeability, easy degradation by endogenous enzymes and off-target effects. 4 To efficiently deliver siRNAs to the target tissues in vivo , a wide variety of non-viral carrier systems, such as cationic lipids and cationic polymers, have been developed to form polyelectrolyte complexes with the oppositely charged siRNA.…”

Section: Introductionmentioning

confidence: 99%

Conjugate Polyplexes with Anti-Invasive Properties and Improved siRNA Delivery In Vivo

Chen

Oupický

2018

Bioconjugate Chem.

View full text Add to dashboard Cite

This study reports on a simple method to prepare siRNA-polycation conjugate polyplexes by in situ thiol-disulfide exchange reaction. The conjugate polyplexes are prepared using thiol-terminated siRNA and a bioreducible branched polycationic inhibitor of the CXCR4 chemokine receptor (rPAMD). The rPAMD-SS-siRNA conjugate polyplexes exhibit improved colloidal stability and resistance against disassembly with heparin, serum, and physiological salt concentrations when compared with control conventional rPAMD/siRNA polyplexes. Coating the polyplexes with human serum albumin masks the positive surface charge and contributes to the enhanced in vitro gene silencing and improved safety in vivo. The conjugate polyplexes display improved in vivo reporter gene silencing following intravenous injection in tumor-bearing mice. Because the conjugate polyplexes retained the ability of rPAMD to inhibit CXCR4 and restrict cancer cell invasion, the developed systems show promise for future combination antimetastatic siRNA therapies of cancer.

show abstract

Non-viral nanocarriers for siRNA delivery in breast cancer

Cited by 81 publications

References 141 publications

An Overview of Various Carriers for siRNA Delivery

An Overview of Various Carriers for siRNA Delivery

Delivery strategies and potential targets for siRNA in major cancer types

Conjugate Polyplexes with Anti-Invasive Properties and Improved siRNA Delivery In Vivo

Contact Info

Product

Resources

About